Phadia Ab

Biomay Ag

Other

Pharmacia Diagnostics Ab

Biomay Produktions- Und Handelsaktiengesellschaft

Centre National De La Recherche Scientifique

Pharmacia Ab

Pharmacia & Upjohn Ab

Ecole Normale Superieure De Cachan

Medizinische Universitat Wien

Worg Pharmaceuticals Co., Ltd.

Valenta, Rudolf

Valent, Peter

Peter Valent

Rudolf Valenta

Dietrich Kraft

Susanne Vrtala

Wolfgang R Sperr

Hans Grönlund

Luca Vangelista

Sylvia Laffer

Birgit Linhart

Monika Grote

Susanne Spitzauer

Annalisa Pastore

Margarete Focke-Tejkl

Ines Swoboda

Sabine Stummfoll

Tanja Ball

Markus Susani

Kerstin Westritschnig

Margit Weghofer

Sabine Stumvoll

Erik Högbom

Jonas Adriansson

Katharina Blatt

Hans Groenlund

Kenneth Roux

Christian Auclair

Jonas Lidholm

Christof Ebner

Pirjo Lehtonen

Friedrich Horak

Marianne Van Hage

Theresia Popow-Kraupp

Hans-Georg Eichler

Renate Reininger

Hans Gr&ouml;nlund

Wolfgang Sperr

Michel Arock

Kenneth H Roux

Vera Mahler

Margarete Focke

Verena Niederberger

Asa Marknell Dewitt

Walter Keller

Anna Twardosz

Johanna Tinhofer

Stefan Florian

Angela Neubauer

Raffaela Campana

Anna Gieras

Ghaith Wedeh

Rosine Saleh

Nadine Mothes

Margit Focke

Maria-Theresa Krauth

Maria-Theresia Krauth

Petra Verdino

Erik Hoegbom

Annalisa c/o Molecular Structure Div Pastore

Sabine Stummvoll

The present invention relates to a human mast cell line corresponding to deposit number CNCM I-4551 and also to the lines derived therefrom, in particular the derived lines corresponding respectively to deposit numbers CNCM I-4552 and CNCM I-4553, and to the uses thereof, in particular for screening for compounds of therapeutic interest.

Human mast cell lines, preparation and uses

An immobilized polypeptide including a polypeptide bound to a surface of a polypeptide array or a chip, wherein the polypeptide has the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:1 lacking the N-terminal methionine, SEQ ID NO:3 lacking the N-terminal methionine, or a combination thereof.

House dust mite allergen

The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.

Vaccine carrier

The present invention relates to a method for identifying hypoallergenic polypeptides and to a corresponding screening method. The invention further relates to hypoallergenic polypeptides identified by the method of the invention and to the prophylactic and therapeutic use of these polypeptides.

Hypoallergenic hybrid polypeptides for the treatment of allergy

Hypoallergenic mosaic antigens assembled from naturally-occurring allergens are disclosed herein. Also disclosed are methods of making such hypoallergenic mosaic antigens, particularly those derived from plant allergens such as timothy grass pollen (Phl p 1 and Phl p 2) and birch pollen (Bet v 1). In a particularly preferred embodiment, the method of making the hypoallergenic mosaic antigen involves the steps of (a) cleaving a naturally-occurring allergen into at least two, preferably at least three non-overlapping peptide fragments and (b) recombining the peptide fragments such that the mosaic antigen includes all or substantially all of the amino acids of the original naturally-occurring allergen, though in a different order.

Hypallergenic mosaic antigens and methods of making same

Methods for desensitization of a mammal suffering from IgE mediated allergy comprise the steps of: administering to said mammal a therapeutically effective amount of an immunogenic and hypoallergenic composition which comprises (i) a Phl p 6 molecule having an N-terminal truncation which makes the molecule at least lack IgE binding capacity, and/or (ii) a Phl p 6 molecule having a C-terminal truncation which makes the molecule at least lack IgE binding capacity, wherein the molecules of (i) and (ii), if employed in combination, together span the complete sequence of Phl p 6, and a pharmaceutically acceptable carrier.

Non-anaphylactic forms of grass pollen Ph1 p 6 allergen and their use

The present invention relates to the use of the combination of tyrosine phosphate inhibitors AMN107 and PKC412 for the preparation of a drug for the treatment of a mast cell-related proliferative disease. The present invention is also drawn to a combination treatment of a tyrosine phosphate inhibitor and a TK-inhibitor that is effective against a mast cell-related proliferative disease, including especially systemic mastocytosis (SM) including aggressive SM (ASM) and mast cell leukemia (MCL).

Compositions for treatment of systemic mastocytosis

The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma. The invention provides a Fab (antibody fragment), having the following characteristics:

Compound for treatment of allergy and asthma

The present invention relates to non-naturally occurring polypeptides derived from fish allergens such as parvalbumin Cyp c 1.01 from carp. The polypeptides display reduced allergenic activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.

Hypoallergenic mutant polypeptides based on fish parvalbumin

A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.

Process for the preparation of hypoallergenic mosaic antigens

The present invention relates to a novel allergen from house-dust mites, to polypeptides derived from said allergen and polynucleotides encoding the same. Furthermore, the invention provides antibodies directed against the allergen and to the use of the polypeptides, polynucleotides and/or antibodies in therapy and diagnosis of allergic disorders.

Allergen from house-dust mites

The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.

Non-anaphylactic forms of grass pollen Phl p 6 allergen and their use

The invention relates to a hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p 6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity. The invention also relates to a hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6. The invention further relates to the use of the hypoallergenic immunogenic molecule or molecule mixture in hyposensitization and diagnosis.

The present invention pertains to polypeptides derived from the timothy grass pollen allergen Phl p 7. The polypeptides display reduced allergen activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination.

Hypoallergenic allergy vaccines based on the timothy grass pollen allergen Phl p 7

The present invention relates to a novel allergen from timothy grass () pollen, Phl p11 as disclosed in SEQ ID NO:2, and use thereof as a reagent and in a diagnositic kit as well as for immunotherapy.

Allergen

Growing community of inventors

Vienna, Austria

Peter Valent